NCT04812470 - Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

May 26, 2025

Study Completion Date

May 26, 2025

Conditions

Metastatic Uveal MelanomaMetastatic Cutaneous Melanoma

Interventions

DRUG

Autologous Tumor Infiltrating Lymphocytes

Administered via hepatic arterial infusion

DRUG

Melphalan

Melphalan will be administered once as an intravenous infusion.

DRUG

Interleukin-2

After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.

Trial Locations (1)

Department of Oncology, Sahlgrenska University Hospital, Gothenburg